共 49 条
[1]
Aebi H., Catalase in vitro, Methods Enzymol, 105, pp. 121-126, (1984)
[2]
Aiyegoro O.A., Okoh A.I., Use of bioactive plant products in combination with standard antibiotics: implications in antimicrobial chemotherapy, J Med Plant Res, 3, pp. 1147-1152, (2009)
[3]
Akhtar M.S., Iqbal Z., Khan M.N., Lateef M., Anthelmintic activity of medicinal plants with particular reference to their use in animals in the indo-Pakistan subcontinent, Small Rumin Res, 38, pp. 99-107, (2000)
[4]
Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller N.W., Storey E., Srivastava R., Rosen B.R., Hyman B.T., Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3- nitropropionic acid, J Neurosc, 13, pp. 4181-4192, (1993)
[5]
Benchoua A., Trioulier Y.I., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Deglon N., Brouillet E., Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin, Mol Biol Cell, 17, pp. 1652-1663, (2006)
[6]
Beyer W.F., Fridovich I., Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions, Anal Biochem, 161, 2, pp. 559-566, (1987)
[7]
Borlongan C.V., Koutouzis T.K., Randall T.S., Freeman T.B., Cahill D.W., Sanberg P.R., Systemic 3- nitropropionic acid, behavioral deficits and striatal damage in adult rats, Brain Res Bull, 36, pp. 549-556, (1995)
[8]
Browne S.E., Ferrante R.J., Beal M.F., Oxidative stress in Huntington's disease, Brain Pathol, 9, pp. 147-163, (1999)
[9]
Chakraborty J., Nthenge-Ngumbau D.N., Rajamma U., Mohanakumar K.P., Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington’s disease, Behav Brain Res, 264, pp. 91-104, (2014)
[10]
Cruz V., Santamaria A., Integrative Hypothesis for Huntington’s disease: A Brief Review of Experimental Evidence Physiol Res, 56, pp. 513-526, (2007)